Related Experiment Videos
[Clinical studies on imipenem/cilastatin sodium in the perinatal period]
1Department of Obstetrics and Gynecology, Juntendo University School of Medicine.
Insights
Imipenem/cilastatin sodium (IPM/CS) demonstrated 100% clinical efficacy in treating perinatal infections like puerperal intrauterine infections and pyelonephritis. This antibiotic combination also achieved an 85.7% bacterial eradication rate with no observed side effects.
Area of Science:
- Perinatal medicine
- Infectious diseases
- Pharmacology
Background:
- Perinatal infections pose significant risks to maternal and infant health.
- Effective antibiotic therapy is crucial during the perinatal period.
- Imipenem/cilastatin sodium (IPM/CS) is a broad-spectrum antibiotic combination.
Observation:
- Clinical studies evaluated IPM/CS in 10 patients with perinatal infections (7 puerperal intrauterine infections, 3 pyelonephritis).
- Patients received intravenous drip infusion of IPM/CS at 0.5 g/0.5 g twice daily.
- Bacteriological assessments were performed before and after treatment.
Findings:
- IPM/CS achieved a 100% clinical efficacy rate (1 excellent, 9 good).
- Bacterial eradication was observed in 12 of 14 strains (85.7%) from 8 patients.
- No adverse effects were reported in patients or their neonates, including abnormal laboratory values.
Implications:
- IPM/CS is a safe and highly effective treatment option for perinatal infections.
- The favorable safety profile supports its use in pregnant and postpartum patients.
- Successful bacterial eradication suggests IPM/CS can reduce the burden of perinatal infections.
Abstract:
Clinical studies were carried out on imipenem/cilastatin sodium (IPM/CS) in the perinatal period, and the results are summarized below. 1. IPM/CS was administered to a total of 10 patients including 7 with puerperal intrauterine infections and 3 with pyelonephritis at a dose of 0.5 g/0.5 g twice daily through intravenous drip infusion. IPM/CS showed satisfactory results. Clinical efficacies were excellent in 1 patient, good in 9 with an efficacy rate of 100%. 2. As for bacteriological evaluation, 12 strains out of 14 detected in 8 patients before the treatment were eradicated upon IPM/CS administration, with an eradication rate of 85.7%. The remaining 2 strains persisted. 3. Neither subjective and objective side effects nor abnormal laboratory test values were observed in any of the patients or their babies.